Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Oncogene

• Publication date

  2007-05-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1210422PMID 17496923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

  2007cited by this paper
• In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway– and microtubule-targeting inhibitors

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

  2006cited by this paper
• Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors

  2006cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される

  2006cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

  2006cited by this paper
• Thematic review series: Lipid Posttranslational Modifications. Geranylgeranylation of Rab GTPases Published, JLR Papers in Press, January 9, 2006.

  2006cited by this paper
• How many drug targets are there?

  2006cited by this paper
• Raf kinases: Oncogenesis and drug discovery

  2006cited by this paper
• Yersinia YopJ Acetylates and Inhibits Kinase Activation by Blocking Phosphorylation

  2006cited by this paper
• Contributions of human tumor xenografts to anticancer drug development.

  2006cited by this paper
• Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome

  2006influential reference
• HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation

  2006cited by this paper
• Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.

  2006cited by this paper
• Inhibitors of the HSP90 molecular chaperone: current status.

  2006cited by this paper
• Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

  2006cited by this paper
• Point mutations of protein kinases and individualised cancer therapy

  2006cited by this paper
• Nuclear factor-κB in cancer development and progression

  2006cited by this paper
• Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

  2006influential reference
• Mechanisms of drug inhibition of signalling molecules

  2006cited by this paper
• Validating cancer drug targets

  2006cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi

  2006cited by this paper
• The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions

  2006cited by this paper
• Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.

  2006cited by this paper
• Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.

  2006cited by this paper
• Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

  2006cited by this paper
• Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.

  2006cited by this paper
• Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.

  2006cited by this paper
• Protein kinases as drug targets in cancer.

  2006cited by this paper
• The mighty mouse: genetically engineered mouse models in cancer drug development

  2006cited by this paper
• Lipid posttranslational modifications. Farnesyl transferase inhibitors.

  2006cited by this paper
• Recurring HRAS mutation G12S in Dutch patients with Costello syndrome

  2006cited by this paper
• The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

  2006cited by this paper
• Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

  2006influential reference
• Mechanisms of cutaneous toxicities to EGFR inhibitors

  2006cited by this paper
• Targeting signal transduction as a strategy to treat inflammatory diseases

  2006cited by this paper
• Recent advances in the research and development of RAF kinase inhibitors.

  2006cited by this paper
• Germline KRAS mutations cause Noonan syndrome

  2006influential reference
• Lapatinib: current status and future directions in breast cancer.

  2006cited by this paper
• Nuclear factor-kappaB in cancer development and progression.

  2006cited by this paper
• BRAF and MEK Mutations Make a Late Entrance

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

  2005cited by this paper
• Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.

  2005cited by this paper
• Emerging role of RAB GTPases in cancer and human disease.

  2005cited by this paper
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• Signaling interplay in Ras superfamily function.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin

  2005cited by this paper
• Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.

  2005cited by this paper
• Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Post-prenylation-processing enzymes as new targets in oncogenesis

  2005cited by this paper
• A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)

  2005cited by this paper
• Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases.

  2005cited by this paper
• Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2

  2005cited by this paper
• Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status

  2005cited by this paper
• Germline mutations in HRAS proto-oncogene cause Costello syndrome

  2005influential reference
• Cancer Statistics, 2005

  2005cited by this paper
• Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• p38 MAP kinase inhibitors: many are made, but few are chosen.

  2005cited by this paper
• Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy

  2005cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005influential reference
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004influential reference
• The Molecular Scaffold KSR1 Regulates the Proliferative and Oncogenic Potential of Cells

  2004cited by this paper
• Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

  2004influential reference
• Fighting cancer by disrupting C-terminal methylation of signaling proteins.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component.

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004influential reference
• Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004influential reference
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004cited by this paper
• Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.

  2004cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Signaling through the epidermal growth factor receptor during the development of malignancy.

  2004cited by this paper
• Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.

  2004cited by this paper

• Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers

  2026cites this paper
• Systems level phosphoproteomics reveals CAMKK2 driven kinase signaling underlying malignant phenotypes in gastric cancer

  2026cites this paper
• Ganglioside GM2 induces epithelial-mesenchymal transition (EMT) in cancer cells in a MEK/ERK/Egr1-dependent transcriptional program.

  2026cites this paper
• Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

  2026cites this paper
• Investigation of exJSRV LTR promoter activity based on transcription factor regulatory networks

  2026cites this paper
• Application of nanoparticles in the therapeutic management of endometrial cancer

  2026cites this paper
• HAX1 overexpression induces osteogenic differentiation of periodontal ligament stem cells via the MEK/ERK signaling cascade.

  2026cites this paper
• Curcumin-inspired monocarbonyl analogues activate caspase-associated apoptosis in human bladder cancer cells

  2026cites this paper
• Glucose availability tunes latent CD8+ T cell expansion potential through a mitogen-independent, mTOR-dependent regulatory switch

  2026cites this paper
• Mechanisms of Gemcitabine Resistance in Pancreatic Cancer

  2026cites this paper
• Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

  2026cites this paper
• Molecular and Functional Insights into Thyrostimulin and Its Subunits-GPA2/GPB5

  2025cites this paper
• Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer

  2025cites this paper
• Yiai Fuzheng decoction inhibits triple-negative breast cancer by remodeling the immune microenvironment

  2025cites this paper
• Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways

  2025cites this paper
• Targeted therapy for liver cancer: Current status and future directions.

  2025cites this paper
• Differential Sensitivity to MEK Inhibitors Highlights Distinct Entosis Mechanisms in BxPC3 and MCF7 Cells

  2025cites this paper
• Linear Causal Discovery with Interventional Constraints

  2025cites this paper
• Forebrain-Specific B-raf Deficiency Reduces NMDA Current and Enhances Small-Conductance Ca2+-Activated K+ (SK) Current

  2025cites this paper
• From resistance to Response: Metallic nanoparticles as game changers in triple negative breast cancer therapy

  2025cites this paper
• Periostin-integrin signaling in hepatocellular carcinoma: from biological function to clinical application

  2025cites this paper
• Inverse modeling unveils governing law of mechano-chemical dynamics of epithelial migration

  2025cites this paper
• Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology

  2025cites this paper
• Sitagliptin Potentiates the Anticancer Activity of Doxorubicin Through ROS-Driven Apoptosis and MMP/TIMP Regulation in HeLa Cells

  2025cites this paper
• Diagnostic potential of the B9D2 gene in colorectal cancer based on whole blood gene expression data and machine learning

  2025cites this paper
• HMMR in human cancers: regulatory mechanism and biological function

  2025cites this paper
• Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.

  2025cites this paper
• Natural killer cell-related gene signature predicts immune cell infiltration and improved survival in bladder cancer.

  2025cites this paper
• Exploring the therapeutic potential of small extracellular vesicles derived from induced pluripotent stem cell in periodontal regeneration.

  2025cites this paper
• Pharmacological Potential and Molecular Targets of Tetrahydrofurofuranoid Lignans From Magnoliae Flos

  2025cites this paper
• RAB26 promotes prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis

  2025cites this paper
• Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance

  2025influential citation
• A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review

  2025cites this paper
• Crystal structures of the phosphorylation mimics of Human Cytosolic Branched Chain Aminotransferase.

  2025cites this paper
• CHI3L1: a key driver in gastritis-to-cancer transformation

  2025cites this paper
• ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases

  2025cites this paper
• R2HaPpY: Rapid-robust phosphotyrosine peptide enrichment using HaloTag-Src SH2 pY superbinder

  2025cites this paper
• Serum pharmacochemistry and network pharmacology reveal the effect and mechanism of licorice extracts on colorectal cancer.

  2025cites this paper
• Unraveling cutaneous histiocytosis: insights into histology, pathogenesis, diagnosis, and treatment pitfalls

  2025cites this paper
• Piperine Induces Apoptosis and Cell Cycle Arrest via Multiple Oxidative Stress Mechanisms and Regulation of PI3K/Akt and MAPK Signaling in Colorectal Cancer Cells

  2025cites this paper
• Harnessing Allostery to Modulate Protein-Protein Interactions: From Function to Therapeutic Innovations.

  2025cites this paper
• Synergistic targeting of cancer-related proteins by benzyl isothiocyanate and caffeic acid: MLSD and cytotoxic mechanisms in MCF-7 cells

  2025influential citation
• Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation

  2025cites this paper
• Survival Outcomes of Patients with BRAF V600E-Mutant Resectable Extrahepatic Colorectal Oligometastases After Upfront Metastasectomy

  2025cites this paper
• Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.

  2025cites this paper
• A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

  2025cites this paper
• KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials

  2025influential citation
• Nano-Drug Delivery Systems Targeting MMPs: A Promising Treatment for Gliomas

  2025cites this paper
• RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

  2025cites this paper
• Overcoming cancer therapy resistance: From drug innovation to therapeutics.

  2025cites this paper
• Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways

  2025cites this paper
• Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions

  2025cites this paper
• Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors

  2025cites this paper
• Multi-view gene panel characterization for spatially resolved omics

  2025cites this paper
• Review on the molecular mechanisms of low-level laser therapy: gene expression and signaling pathways

  2025cites this paper
• Thiazolidinedione derivatives: emerging role in cancer therapy

  2025cites this paper
• Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold

  2025cites this paper
• Inhibition of HDAC6 elicits anticancer effects on head and neck cancer cells through Sp1/SOD3/MKP1 signaling axis to downregulate ERK phosphorylation.

  2025cites this paper
• Efficient and Explainable Virtual Screening of Molecules through Fingerprint-Generating Networks Integrated with Artificial Neural Networks

  2025cites this paper
• GALNT5 promotes migration and invasion of pancreatic ductal adenocarcinoma cells by activating Erk signaling pathway.

  2025cites this paper
• Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology.

  2025cites this paper
• 3,4-dihydroxybenzalacetone from Phellinus linteus reduces glial activation, mitigates oxidative stress and inflammation, and preserves retinal function in ischemia-reperfusion-like injury.

  2025cites this paper
• Decoding allosteric landscapes: computational methodologies for enzyme modulation and drug discovery

  2025cites this paper
• Ras activation by hydrostatic pressure involves GDP release and is enhanced by GAP and GEF in vitro.

  2025cites this paper
• MMP28 recruits M2-type tumor-associated macrophages through MAPK/JNK signaling pathway-dependent cytokine secretion to promote the malignant progression of pancreatic cancer

  2025cites this paper
• EGFR in Placental Health and Disease: Pathways, Dysfunction, and Chemical Disruption.

  2025cites this paper
• Pro-Apoptotic Effects of Anandamide in Human Gastric Cancer Cells Are Mediated by AKT and ERK Signaling Pathways

  2025cites this paper
• A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

  2025cites this paper
• Molecular mechanisms of GDNF/GFRA1/RET and PI3K/AKT/ERK signaling interplay in neuroprotection: Therapeutic strategies for treating neurological disorders.

  2025cites this paper
• A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members

  2025cites this paper
• Itaconate targets the ERK2 signal to suppress estrogen receptor-positive breast cancer cell growth.

  2025cites this paper
• Integrated omics reveals the regulatory role of PKCα in Sertoli cell proliferation and apoptosis through the MAPK/ERK signaling pathway in goose testis

  2025cites this paper
• L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity

  2025cites this paper
• Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma.

  2025cites this paper
• Association Between miR-539 and miR-6824 and Their Target Gene, MAP2K1, Expression Level in Oral Cancer

  2025cites this paper
• Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies.

  2025cites this paper
• Triad-LMF: A Hierarchical Low-Rank Multimodal Fusion Framework for Robust Cancer Subtype Classification Using Multi-Omics Data

  2025cites this paper
• Ukufundiswa kwemibhalo yobuciko emakilasini esiZulu ngenhloso yokufundisa abafundi ngekhono lokuhlaziya izinkinga zomphakathi

  2025cites this paper
• Microneedles loaded with PD-L1 inhibitor and doxorubicin GelMA hydrogel for melanoma immunochemotherapy

  2025cites this paper
• RASopathies. Part I: Genetics and therapeutic considerations.

  2025cites this paper
• Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF.

  2025cites this paper
• Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development

  2025cites this paper
• Actin-modulated nuclear shape controls adaptive reprogramming in cancer-associated fibroblasts

  2025cites this paper
• Mutation-specific structural changes in BRAF: understanding dimerization and drug binding for targeted therapy.

  2025cites this paper
• Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway

  2025cites this paper
• Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma

  2025cites this paper
• Epigenetic-mediated positive feedback loop facilitates the progression of lung adenocarcinoma

  2025cites this paper
• Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

  2025cites this paper
• 1,2-Naphthoquinone promotes cell migration through EGFR-ERK signaling pathway in human A549 cells.

  2025cites this paper
• Ursolic Acid from Carissa carandas L. as a Multi-Target Agent Against NSCLC: An Integrative In Silico and In Vitro Study.

  2025cites this paper
• Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells

  2024cites this paper
• Withanolides: Promising candidates for cancer therapy

  2024cites this paper
• Investigation of the interaction between S-isoalkyl derivatives of the thiosalicylic acid and human serum albumin

  2024cites this paper
• The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

  2024cites this paper
• Molecular and immunohistochemical markers in appendiceal mucinous neoplasms: A systematic review and comparative analysis with ovarian mucinous neoplasms and colorectal adenocarcinoma.

  2024cites this paper
• Signaling pathway regulators in preimplantation embryos

  2024cites this paper
• RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP

  2024cites this paper
• Discovery of anti-tumor small molecule lead compounds targeting the SH3 domain of c-Src protein through virtual screening and biological evaluation.

  2024cites this paper
• Exploring the inhibitory potential of xanthohumol on MEK1/2: a molecular docking and dynamics simulation investigation

  2024cites this paper
• Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy.

  2024cites this paper